跳至主要内容
临床试验/ACTRN12612001135808
ACTRN12612001135808进行中(未招募)2 期

An 8 week randomised, double blind, placebo controlled clinical trial investigating the effects of 3000mg daily trans-resveratrol on peripheral insulin resistance, systemic inflammation, hepatic steatosis, abdominal adipose tissue topography, plasma metabolic markers, gene expression in peripheral blood mono-nuclear cells and anthropometry in male patients with non-alcoholic fatty liver disease, aged 18-65years.

Metro-South Queensland health0 个研究点目标入组 20 人开始时间: 2012年10月24日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
Male

入选标准

  • Diagnosed with NAFLD on ultrasound

排除标准

  • -Viral hepatitis or other known cause for non-alcoholic liver disease such as use of hepato-toxic medications (eg. tamoxifen, methatrexane)
  • -Presence of metallic implants unsuitable for magnetic resonance, or a pace-maker
  • -Cirrhosis
  • -Ethanol consumption above 40g daily
  • -Type 1 or 2 diabetes
  • -Allergy to polyphenols
  • -Inability undergo all investigations

研究者

发起方
Metro-South Queensland health

相似试验